학술논문

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2021, 39 15, 3p. Supplement: S
Subject
Language
English
ISSN
15277755